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Summary.-Extensive investigation of 3-(p-chlorophenyl)-2,3-dihydro-3-hydroxy-
thiazolo[3,2-a]-benzimidazole-2-acetic acid (Wy-13,876) in BDF1 mice implanted
with Lewis lung tumour has shown that it is an effective anti-tumour and anti-
metastatic agent. In vitro examination using HEp-2 human epidermal tumour
cells has indicated that Wy-13,876 is not cytotoxic. When mice implanted with
Lewis lung tumour and treated with Wy-13,876 are also injected with anti-thymocyte
serum, an increase in lung metastases is observed suggesting that thymocyte activity
is involved in the drug's mechanism of action. An increase in peripheral T lympho-
cytes observed in rats 18 h after a single oral dose of Wy-13,876 further supports
this possibility. When Wy-13,876 is given to tumour-bearing mice in combination
with low, ineffective doses of 5-fluorouracil or cyclophosphamide, further reduction
of primary tumour growth is observed.
IT HAS BEEN reported (Stjernsward et
al., 1972) that radiation for mammary
carcinoma lowers the circulating level of
thymus (T) lymphocytes for at least
1 year, and these workers suggest that the
observed increase in metastases might
be related to the lymphopaenia. Other
studies (Renoux and Renoux, 1972) have
indicated that levamisole inhibits the
growth and subsequent lung metastases
of Lewis lung (3LL) tumour in C57B1
mice. Using the Lewis lung (3LL) tumour
in BDF1 mice, we have modified a model
system described by James and Salsbury
(1974) to study the anti-tumour and
anti-metastatic activity ofnew compounds
including potential anti-helminthic agents
chemically related to levamisole (Bell
and Wei, 1976). The most effective of
these was found to be 3-(p-chlorophenyl)-
2,3 - dihydro - 3 -hydroxythiazolo [3,2 -a] -
benzimidazole-2-acetic acid (Wy-13,876,
NSC 208828).
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MATERIALS AND METHODS
Six to 8-week-old male BDF1 mice
weighing 19-21 g were used for the tumour
studies. This strain is used to conform
with Protocol 1.400 of the Drug Research
and Development Division of Cancer Treat-
ment, National Cancer Institute. Growth
of the Lewis lung carcinoma in the F1
generation of this hybrid is completely
comparable with that obtained in the
syngeneic C57B1 mouse. The latter line
was always employed for stock tumour
growth (Geran et al., 1972). Subcutaneous
trochar implants of 2-4mm fragments of
3LL tumour were made in the axillary
* A portion of this study was presented at the 66th Annual Meeting of the American Association for
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region. Starting 24 h later the mice received
daily intraperitoneal injections of Wy-13,876,
or levamisole (kindly supplied by Janssen
Laboratories, Belgium), suspended in a
solution composed of 1 part of0-500 carboxy-
methylcellulose (CMC, Methocel, Dow Chemi-
cal Company, Midland, Mich.) and 2 parts
of physiological saline, while the control
animals received only the CMC-physiological
saline solution. At the end of the experi-
mental period the mice were killed, the
tumour and lungs excised, the primary tu-
mours uAeighed for the determination of
T/C ratios (mean tumour weight for treated
divided by mean tumour weight for control
animals x 100) and the lungs examined for
metastases, either by observation of the
total lung surface with a dissecting micro-
scope or by histopathological examination.
The histopathological examination involved
making serial transverse sections of the
lungs at intervals of several millimetres
until the entire lung mass was used. Twelve
to 14 sections were obtained per lung. A
haernatoxylin and eosin stain was used and
the slides wNere examined microscopically
at both low and high magnification so as
to identify all metastases, including early
ones. All slides were coded before examina-
tion by the pathologist to create a blind study.
In order to test the importance of viable
circulating lymphocytes for the antitumour
activity of Wy-13,876 and levamisole, anti-
thymocyte serum (ATS, Microbiological Asso-
ciates, Rockville, Md) was administered
undiluted by the intraperitoneal route to
separate groups of mice implanted with
Lewis lung (3LL) tumour at doses of 0-1
ml/mouse one day before tumour implanta-
tion and 1 and 5 days after implantation
for the first wNeek then twice a week for
the remainder of the experiment. Positive
control groups that were given cyclophos-
phamide (Cytoxan, Mead Johnson Labora-
tories, Evansville, Ind.) as wN-ell as control
groups that did not receive any compound,
with and without the injection of ATS,
were also included in this experiment.
Treatment was stopped on Day 14 and the
animals were kept for 4 additional days
before killing. The primary tumours erere
weighed and the lungs were preserved in
formalin and subjected to examination under
a dissecting microscope for the determination
of the number of lung metastases.
To study the effect of Wy-13,876 or
levamisole on T lymphocyte formlation,
male CDW rats in groups of 4 were given
various doses of the drugs suspended in
wvater by gavage, the control rats receiving
only water. The rats were fasted overnight,
and 18 h after drug administration, blood
samples were taken by cardiac puncture
using heparinized vacutainers (Becton Dickin-
son and Co., Rutherford, N.J.). The blood
from the rats in each dosage group was
pooled, diluted with an equal volume of
Hanks' modified balanced salt solution
(HMBSS), 8 ml layered on a 4 ml gradient
containing 10 parts of 5000 Hypaque with
16 parts of cold 2% methyleellulose (15 ct/s
Dow Chemical Co., Midland, Mich.) and the
lymphocytes separated at the interface after
centrifugation according to the procedure
of Boyum (1968). The lymphocytes were
then washed twAice with HMBSS.
The incubation system for rosette forma-
tion, patterned after the procedure of Siegel
and Sherman (1972), consists of 0 1 ml
of lymphocyte suspension (1-6 x 106 cells/
ml), 0*1 ml of guinea-pig red blood cells
(6-4 x 106 cells/ml) and 0 1 ml of foetal calf
serum in HMBSS. The tubes, set up in
triplicate for control and experimental groups,
are incubated in a shaker bath for 60 min
at 370C, the number of rosettes per 100
thymocytes from each of the 3 tubes counted
under the microscope, and the results
expressed as the mean value of rosettes
(T lymphocytes) for the experimental group,
divided by the mean value for the control
group.
A series of experiments -x'as also con-
ducted wiith mice using the described Lewis
lung system in wNhich combination of Wy-
13,876 wAith low, anti-tumour doses of cyclo-
phosphamide and 5-fluorouracil (Roche La-
boratories, Nutley, N.J.) were used.
Cytotoxicity of Wy-13,876 was deter-
mined using HEp-2 human epidermal tumour
growi-n as monolayers in tissue culture flasks
in a basal serum medium according to the
established procedure of Geran et al. (1972).
Various concentrations of Wy-13,876 were
prepared in demineralized water and added
to the culture tubes, which wNere then
incubated at 370C until at least a six-fold
increase in total protein was obtained in
the control tubes, as indicated by the Lowry
assay. Compounds are considered active in
this test if they show, an ED50 of < 4 ,tg/ml
as an average of 2 assays.
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Daily intraperitoneal injections of dif-
ferent doses of Wy-13,876 were given to
separate groups of 10 BDF1 mice for 10
consecutive days to determine the in vivo
toxicity of the compound according to the
procedure of Reed and Muench (1938).
RESULTS
Wy-13,876 was notinhibitory to HEp-2
(human epidermal tumour) in vitro below
198 ,ug/ml, indicating that the compound
is not cytotoxic. Tests to determine in
vivo toxicity of Wy-13,876 (Table I)
TABLE I.-Toxicity of WVy-13,876 in BDF,
Mice
No. of
doses
10
10
10
10
Cumulative
r -
A
No. alive No. dea(d
3 18
6 11
12 4
22 0
0O Dead
85-7
64-7
25-0
0.0
revealed that it could be administered
safely by the intraperitoneal route to
mice at doses as high as 200 mg/kg/day
for 10 days. The chronic LD50 for Wy-
13,876 with 10 daily doses was 263 mg/kg.
The highest repeated dose of levamisole
that could be given under our test condi-
tions was 25 mg/kg/day.
The results of a comparative study
of Wy-13,876 with a positive control
cyclophosphamide and with levamisole
(Table II) show some inhibition ofprimary
tumour growth by Wy-13,876.
Table III shows the dose responses
obtained for Wy-13,876 and levamisole.
No significant inhibition was observed
with Wy-13,876 at 12.5 or 25 mg/kg.
At 50 and 100 mg/kg inhibition ofprimary
tumour growth is seen and at 150 mg/kg
a significant T/C ratio of37%o is observed.
Levamisole did not depress primary tu-
mour growth at either 12-5 or 25 mg/kg.
The effect of Wy-13,876 on primary
tumour growth and lung metastases, as
monitored by histopathological examina-
tion, is shown in Table IV. Primary
tumour weight reduction was seen at
both the 100 and 150 mg/kg doses,
although only the 150 mg/kg dose brought
the T/C value below the 420% level. The
histopathological study of the lungs from
these mice indicated that at the 150
mg/kg dose, 6 of 10 mice showed no
metastases whereas the lungs of the
remaining 4 mice showed 1, or 3 to 5
indications of small metastases. At the
100 mg/kg dose, 2 mice showed no meta-
stases; 4 mice, 3-5tiniy metastases; 2 mice,
6-9 metastases and the final 2, 10-21
metastases. The cyclophosphamide con-
trol showed no lung metastases and the
negative controls showed a spectrum
of metastatic involvement. In compari-
son with the lungs from the CMC control
mice 800 metastases were observed in
the lungs ofthe mice dosed with 150 mg/kg
of Wy-13,876 and 52% in the lungs of
those given 100 mg/kg.
Table V shows the results of the
experiment in which ATS was used to
suppress thymocyte function in mice
receiving either Wy-13,876, levamisole,
cyclophosphamide or CMC control solu-
TABLE II.-Activity of Wy-I 3,876, Levarnisole and Cyclophospharnide against Lewis Lung
(3LL) Tumour
Compound
Wy- 13,876
Levamisole
Cyclophosphami(le
Control§
Dose
(mg/kg)
100
25
20
Meani wt
chg. (g)
+1 *8
+0 9
0.0
+2 0
D/T*
1/10
1/10
0/10
0/20
N
9
9
10
20
0°, (T/C)t
34
79
17
AMean tumour wt
(g) s.e.t
0 471 0 * 2
1 *089-0-02
0-234±01-
1*380 0-2
P value
<0 05
N.S.
<0-001
* Dead/total inumber of animals.
t Meatn tumouir weight for treated/mean tumtour weight for cotntrol mice x 100.
I Standard error.
§ Dosed with 0-2% CAIC in physiological saline.
Ii bold type: T/C ratio <420, i.e. active 'lose of compoundI.
Dose
(mg/kg)
400
300
200
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TABLE III.-Dose Response of Wy-13,876 and Activity ofLevarmisole against Lewis Lung
(3LL) Tumour
Dose Mean wt Mean tumour wt
Compound (mg/kg) chg. (g) D/T* N 00 (T/C)t (g) I s.e.t P Value
Wy-13,876 12-5 +1-6 0/10 10 66 1-68±0-2 <0 01
Wy-13,876 25 +1-2 0/10 10 74 1-89±0-3 <0-1
Wy-13,876 50 +1-2 0/10 10 48 1-23±0-1 <0 001
Wy-13,876 100 +0 7 2/10 8 47 1-20±0-2 <0 001
Wy-13,876 150 -0.5 2/10 8 37 0 95±0 1 <0-001
Wy-13,876 200 +0 5 2/10 8 67 1-70±0-2 <0-02
Levamisole 12-5 +0-6 0/10 10 78 1 99±0 2 <0-1
Levamisole 25 +1-3 4/10 6 71 1-80±0-3 <0-1
Control§ +2-2 0/20 20 2-54±0 2
* Dead/total number of animals.
t Mean tumour weight for treated/mean tumour weight for control mice x 100.
t Standard error.
§ Dosed with 0-2% CMC in physiological saline.
In bold type: T/C ratio < 42%, i.e. active dose of compound.
TABLE IV.-Activity of Wy-13,876 against Lewis Lung (3LL) Tumour and Histopatho-
logical Evaluation of Lung Metastases
AMice with ltng metastases
Mean Meta-
wt Mean No. of metastases stases
Dose chg. % tumour wt P A (% of
Compound (mg/kg) (g) D/T* N (T/C)t (g) ± s.e.t Value 0 1-2 3-5 6 9 10-21 cont.)
Wy-13,876 150 -0 3 0/10 10 41 0-75±03 3 <0-02 6 1 3 0 0 8
Wy-13,876 100 +0 3 0/10 10 54 1-0110 2 <0-05 2 0 4 2 2 52
Cyclo-
phosphamide 20 -2-0 0/10 10 17 0-32±0-1 <0-001 10 0 0 0 0 0
CMC control -0-6 0/20 20 1-86-40-2 1 4 6 2 6 100
* Dead/total number of animals.
t Mean tumour weight for treated/mean tumour weight for control mice x 100.
t Standard error.
In bold type: T/C ratio < 42%, i.e. active dose of compound.
TABLE V. Effect of Anti-thymocyte Serum on Primary Tumour Growth and Lung
Metastases in Lewis Lung (3LL) Tumour-implanted Alice Treated with Wy-13,876 or
Levamisole
Average
no. of MNea-1 lung
Dose Mean wt tumour wt meta-
Compound (mg/kg) ATS§ chg. (g) D/T* N 00 (T/C)t (g)±s.e. P Value stases¶
Wy-13,876 100 No -0 5 1/9 9 48 2-03 0-06 <0-05 2 - 4
Wy-13,876 100 Yes -0-6 4/10 6 66 1 -98±0-5 N.S. 6-3
Levamisole 25 No -0 3 2/10 8 59 2*54 0 5 a < 0 * 1 3 4
Levamisole 25 Yes -1-8 5/10 5 63 1 92-4-0 8 N.S. 2-5
Cyclophosphamide 20 No -3 *1 0/9 9 23 1*00--0 2 <0*001 0
Cyclophosphamide 20 Yes 9/10 1 6 - 0
CMC control No -0-2 0/9** 9 4-26±0-6 12-0
CMC control Yes -0-8 2/10 8 3-02-04 17-5
* Dead/total number of animals.
t Mean tumour weight for treated/mean tumour weight for control mice x 100.
t Standard error.
§ Antithymocyte serum (Microbiological Associates).
¶ As observed with a (lissecting microscope.
** One animal killed to evaluate metastatic spread on Day 14.
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tions, in comparison with similarly treated
mice that did not receive ATS. In this
experiment the mice treated with Wy-
13,876 did not show any difference in
primary tumour weight, regardless of
whether they received ATS. A difference
in primary tumour weight is observed
for those animals that received levamisole.
A lesser number of lung metastases was
found for the mice that received Wy-
13,876, but not ATS, in comparison
with those which received Wy-13,876
plus ATS. Little difference was observed
between the levamisole-treated mice
whether they did or did not receive
ATS.
Lung metastases were not found in
mice that received cyclophosphamide
without ATS, but 9 of 10 of the cytoxan
treated mice that also received ATS
died. Increased lung metastases were
also found in the ATS-treated control
mice.
An initial examination of the effects
of different doses of Wy-13,876 or leva-
misole on T lymphocytes (Table VI), as
demonstrated by rosette formation, show-
ed some activity for Wy-13,876 at 75
mg/kg, and a doubling of T lymphocytes
in comparison with the controls at 100
and 200 mg/kg. Levamisole did not in-
crease T lymphocytes at 75 mg/kg, but
slight activity at 100 mg/kg and good
activity at 150 mg/kg were observed.
Table VII shows the effects of com-
TABLE VI.-Effect of Wy-13,876 and
Levamisole on T-Lymphocytes as Mea-
sured by Rosette Formation 18 h after a
Single Oral Dose
Compound (n
Wy-13,876
Levamisole
Control
Wy-13,876
Levamisole
Control
Wy-13,876
Levamisole
Control
Dose
rng/kg)
75
75
No. ofadhering
thymocytes
(Mean ± S.D.
of 3 tubes)
4-3±0-6 23±06
0 3 0±1-0
100 7-0±2-0
100 5-31-0-6
3-7±0 6
200 6-3±1 * 1
150 50±0
3-0±0
Rosette
formation*
E/C ratio
1 4
0-8
1-9
1 4
2-1
1- 7
* Number of rosettes per 100 thymocytes are
determined for 3 groups of 100 cells from 3 separate incubation tubes for the experimental and control
groups and the means of these values are used to
calculate the ratio.
binations of Wy-13,876 or levamisole
with 5-fluorouracil on primary tumour
growth in mice. In this experiment a
good T/C ratio was found for the 150
mg/kg dose of Wy-13,876, and its com-
bination with a low dose of 5-fluorouracil
(10 mg/kg) substantially lowered the T/C
ratio.
Analysis of the tumour weight dif-
ference between the Wy-13,876 treated
group and the group treated with Wy-
13,876 and 5-fluorouracil did not show
a significant statistical difference between
the 2 groups. A comparatively low T/C
TABLE VII.-Evaluation of the Capacity of Low Doses of 5--Pluorouracil to Potentiate the
Anti-Lewis Lung (3LL) Tumour Activity of Wy-13,876 and Levamisole
Compouiid
Wy- 13,876
Levamisole
5-Fluorouracil
Wy- 13,876 +
5-Fluorouracil
Levamisole +
5-Flutorouracil
CMC control
Dose
(mg/kg)
150
25
10
150
10
25
10
Mean wt
chg. (g)
+0-2
0-1
-4-4
-3-2
D/T*
0/10
1/10
0/10
0/10
N
10
9
10
10
-4 - 4 1/10 10
-0-5 1/20 18§
% (T/C)t
39
35
53
25
Mean tumour wt
(g) ± s.e.t
0-60±0-1
0 -54±0* 2
0-80±0-2
0 37±0-1
P Value
<0-001
<0-01
<0-02
<0-01
36 0-55±0*1 <0-001
1-52±0-2
* Dead/total number of animals.
t AMean tumour weight in treated/mean tumour weight for control mice x 100. I Standard error.
§ One "Ino take " eliminated from calculation.
In bold type: T/C ratio 42 %, i.e. active dose of compound.
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TABLE VIII.-Evaluation of the Capacity of Low Doses of Cyclophosphamide to Potentiate
the Anti-Lewis Lung (3LL) Turnour Activity of Wy-13,876
Compoun(d
Wy- 13,876
Cyclophosphamide
Cyclophosphamide
Wy-13,876 +
Cyclophosphamidle
Wy-13,876 +
Cyclophosphami(le
CMC control
Dose
(mg/kg)
100
10
5
100
10
100
5
MNean wt
chg. (g)
0()
+0-1
-0- 6
-1 0
D/T*
0/10
0/10
0/10
0/9
N
10
10
10
9
-1-6 0/10 10
0 * 2 0/20 20
o, (r/c)t
53
90
75
38
Mean tumour wvt
(g) t s.e.I
0-98±0-2
1 * 66 ±0 - 3
1 *38±0-3
0 70 0
P Value
<0-01
N.S.
N.S.
<0-001
44 082 ±0 2 <0.01
I1-84 -0-2
* Dead/total number of animals.
t Mean tumour weight in treated(/mean tutmour wseight for control mice x 100.
I Standard error.
In bol(d type: T/C ratio < 42% i.e. active (lose of compouin(tl.
value was obtained in the experiment
in which levamisole was given to tumour-
implanted mice; a very small reduction
in T/C ratio was found when levamisole
was combined with the low dose of
5-fluorouracil.
The results with 2 low doses of
cyclophosphamide, 5 and 10 mg/kg, in
combination with a 100 mg/kg dose of
Wy-13,876 indicated a reduction of pri-
mary tumour growth at both cyclo-
phosphamide levels (Table VIII), but
the difference between these 2 groups and
the group that received Wy-13,876 alone
was not statistically significant.
In no instance in these experiments
did the weight changes observed in mice
treated with Wy-13,876 exceed those
observed for the controls.
DISCUSSION
The results show that Wy-13,876
inhibits primary Lewis lung tumour
growth in mice and has significant activity
in preventing lung metastases. Parallel
studies indicate that levamisole has only
very moderate activity in preventing
primary tumour growth under these
conditions. The dose response examina-
tion of the activity of Wy-13,876 shows
optimal anti-tumour activity at 150mg/kg,
and a good indication of activity is
observed at the 50 and 100 mg/kg doses.
In these experiments tumour weight
reductions were frequently observed which
were statistically significant but were
insufficient to meet the National Cancer
Institute protocol requirement for activity,
that is T/C ratios of less than 4200.
In the Tables of results where the data
did meet the NCI criterion the T/C
values are underlined.
Wy-13,876 did not show cytotoxic
activity against HEp-2 human epidermal
tumour cells (Geran et al., 1972) and the
chronic LD50 for this compound in mice
of 263 mg/kg suggests a good margin
of safety for its use.
Wy-13,876 treated mice injected with
ATS did not show any significant difference
in primary tumour weight but the increase
in lung metastases suggests that cell-
mediated immune mechanisms, possibly
through increased activity of T lympho-
cytes, plays a part in the reduction of
these metastases.
The average number of lung meta-
stases found for the levamisole + ATS-
treated mice was slightly less than the
number found for the matched levamisole-
treated animals. These results can be
explained either by the loss of 5 of 10
mice in the ATS-treated group, or by the
possibility that levamisole is a weak
immunostimulant and thymocytes play
only a minimal role in its mechanism of
action. The first reason seems to be
the more likely one since the differential
in the average number of metastases in
the control ATS-treated and untreated
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group of mice is much greater and the
number of lung metastases in the control
groups is very much higher. The rosette
test, which indicates the capacity to
stimulate the generation of T lympho-
cytes, shows that both Wy-13,876 and
levamisole increase T lymphocyte levels
in rats. This experiment further suggests
that increased T lymphocyte levels may
be involved in the anti-metastatic mech-
anism.
The final experiments concern a study
ofthe capacity ofWy-13,876 to potentiate
the anti-tumour activity of 5-fluorouracil
and cyclophosphamide and the effect
of levamisole on 5-fluorouracil activity.
Chirigos, Pearson and Pryor (1973) have
reported on the value of combining
chemotherapy and immunostimulation in
a murine leukaemia and they have shown
that, when levamisole is combined with
low doses of 1,3 bis(2-chloroethyl)-1-
nitrosourea, a higher percentage of long-
term survivors is found. In our experi-
ments a low dose of 5-fluorouracil had at
least an additive anti-tumour effect with
Wy-13,876, as indicated by the T/C
ratios, but it did not affect the activity
of levamisole. Low doses of cyclophos-
phamide also appeared to augment the
anti-tumour activity ofWy-13,876 by this
criterion.
We thank Dr Peter Wei for the
synthesis of Wy-13,876, Dr Walter E.
Tucker for developing the histopatho-
logical technique for the examination
of lung tissue, Dr Allen J. Steinberg
(Philadelphia General Hospital) for the
evaluation of the lung tissues reported
in this study and Manuela Selles and
Richard L. Bloom for valuable technical
assistance. Special acknowledgment is
made to Shirley Fenichel, whose indication
of the importance of a resistance factor
in cancer, andwhose encouragement, made
this work possible.
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